← Leaderboards
Betty Sue Pace
Augusta University
$15,499,214
Attributed
$17,353,109
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,353,109 · 10
By mechanism
R01$7,347,421 · 3
R25$6,351,662 · 2
R33$2,275,984 · 1
R42$1,073,855 · 1
K14$133,650 · 1
P60$94,037 · 1
Top collaborators
- Louis H Junker3 shared
- Abdullah Kutlar3 shared
- Robert Michael Williams3 shared
Most similar at Augusta University
Same institution · by research overlap
- Abdullah Kutlar$13,235,740
- Xingguo Zhu$1,740,580
Others in their field
Top investigators on “Sickle Cell Anemia”
- Russell E Ware · Duke University$48,435,687
- Michael Rutledge Debaun · Vanderbilt University Medical Center$38,268,866
- Martin H. Steinberg · Boston Medical Center$25,628,557
- Michael L. Terrin · Clinical Trials And Surveys Corporation$23,855,067
- Barbara L Kroner · Research Triangle Institute$21,141,016
- Garret A Fitzgerald · University Of Pennsylvania$20,602,198
Research focus
Sickle Cell AnemiaBaseHematological DiseaseTranscription FactorClinical ResearchHemoglobinGene ExpressionDesignAfrican AmericanGlobinSuccessFetal HemoglobinNational Heart, Lung, And Blood InstituteGenesIn VivoMediatingFundingGamma GlobinUnited StatesFetalChromatinGrantResearch PersonnelGene Expression Regulation
Grant awards (59)
Phase I study of panobinostat in adults with sickle cell disease: novel approach to recruitment and retention$750,712
R33 · FY2025 · HL
Phase I study of panobinostat in adults with sickle cell disease: novel approach to recruitment and retention$743,146
R33 · FY2024 · HL
PRIDE-Functional and Translational Genomics of Blood Disorders$342,360
R25 · FY2024 · HL · contact PI
Phase I study of panobinostat in adults with sickle cell disease: novel approach to recruitment and retention$782,126
R33 · FY2023 · HL
Development of fetal hemoglobin inducers targeting epigenetic and oxidative stress mechanisms$399,708
R01 · FY2023 · HL · contact PI
PRIDE-Functional and Translational Genomics of Blood Disorders$344,054
R25 · FY2023 · HL · contact PI
PRIDE-Functional and Translational Genomics of Blood Disorders$468,254
R25 · FY2022 · HL · contact PI
Development of fetal hemoglobin inducers targeting epigenetic and oxidative stress mechanisms$362,000
R01 · FY2022 · HL · contact PI
PRIDE-Functional and Translational Genomics of Blood Disorders$468,254
R25 · FY2021 · HL · contact PI
Development of fetal hemoglobin inducers targeting epigenetic and oxidative stress mechanisms$366,600
R01 · FY2021 · HL · contact PI
In Vivo Studies of a Novel HDAC Inhibitor for Treating Hemoglobin Disorders$550,046
R42 · FY2020 · HL · contact PI
PRIDE-Functional and Translational Genomics of Blood Disorders$468,636
R25 · FY2020 · HL · contact PI
Development of fetal hemoglobin inducers targeting epigenetic and oxidative stress mechanisms$379,219
R01 · FY2020 · HL · contact PI
In Vivo Studies of a Novel HDAC Inhibitor for Treating Hemoglobin Disorders$24,589
R42 · FY2020 · HL · contact PI
In Vivo Studies of a Novel HDAC Inhibitor for Treating Hemoglobin Disorders$499,220
R42 · FY2019 · HL · contact PI
PRIDE-Functional and Translational Genomics of Blood Disorders$469,871
R25 · FY2019 · HL · contact PI
Gamma Globin Induction: Molecular and Cell-Based Strategies$414,337
R01 · FY2017 · HL · contact PI
PRIDE: Functional and Translational Genomics of Blood Disorders$343,213
R25 · FY2017 · HL · contact PI
Gamma Globin Induction: Molecular and Cell-Based Strategies$432,219
R01 · FY2016 · HL · contact PI
PRIDE: Functional and Translational Genomics of Blood Disorders$368,053
R25 · FY2016 · HL · contact PI
Gamma Globin Induction: Molecular and Cell-Based Strategies$17,472
R01 · FY2016 · HL · contact PI
Gamma Globin Induction: Molecular and Cell-Based Strategies$386,532
R01 · FY2015 · HL · contact PI
PRIDE: Functional and Translational Genomics of Blood Disorders$340,667
R25 · FY2015 · HL · contact PI
Gamma Globin Induction: Molecular and Cell-Based Strategies$388,730
R01 · FY2014 · HL · contact PI
PRIDE: Functional and Translational Genomics of Blood Disorders$295,099
R25 · FY2014 · HL · contact PI
PRIDE-Functional and Applied Genomics of Blood Disorders$308,769
R25 · FY2013 · HL · contact PI
PRIDE-Functional and Applied Genomics of Blood Disorders$364,122
R25 · FY2012 · HL · contact PI
Gamma Globin Induction: Molecular and Cell-Based Strategies$372,500
R01 · FY2011 · HL · contact PI
PRIDE-Functional and Applied Genomics of Blood Disorders$350,000
R25 · FY2011 · HL · contact PI
Gamma Globin Induction: Molecular and Cell-Based Strategies$372,750
R01 · FY2010 · HL · contact PI
PRIDE-Functional and Applied Genomics of Blood Disorders$299,999
R25 · FY2010 · HL · contact PI
Gamma Globin Induction: Molecular and Cell-Based Strategies$374,992
R01 · FY2009 · HL · contact PI
Sickle Cell Disease Research Center (SCDRC) Summer Institute/Mentoring Program$307,556
R25 · FY2009 · HL · contact PI
Genome-wide Association Study: Fetal Hemoglobin Phenotypes in Sickle Cell Disease$76,500
R56 · FY2009 · DK · contact PI
Sickle Cell Disease Research Center (SCDRC) Summer Institute/Mentoring Program$72,955
R25 · FY2009 · HL · contact PI
Gamma Globin Induction: Molecular and Cell-Based Strategies$400,685
R01 · FY2008 · HL · contact PI
Sickle Cell Disease Research Center (SCDRC) Summer Institute/Mentoring Program$280,800
R25 · FY2008 · HL · contact PI
Sickle Cell Disease Research Center (SCDRC) Summer Institute/Mentoring Program$270,000
R25 · FY2007 · HL · contact PI
Mechanisms for Stat 3-Mediated Gamma-Globin Gene Silenc*$281,658
R01 · FY2006 · HL · contact PI
Sickle Cell Disease Research Center (SCDRC) Summer Institute/Mentoring Program$189,000
R25 · FY2006 · HL · contact PI
Mechanisms for Stat 3-Mediated Gamma-Globin Gene Silenc*$38,371
R01 · FY2006 · HL · contact PI
Mechanisms for Stat 3-Mediated Gamma-Globin Gene Silenc*$347,788
R01 · FY2005 · HL
Mechanisms for Stat 3-Mediated Gamma-Globin Gene Silenc*$11,213
R01 · FY2005 · HL
Mechanisms For p38 MAP Kinase DependentT Gene Induction$346,076
R01 · FY2004 · HL
Mechanisms for Stat 3-Mediated Gamma-Globin Gene Silenc*$269,300
R01 · FY2004 · HL
Mechanisms for Stat 3-Mediated Gamma-Globin Gene Silencing$26,163
R01 · FY2004 · HL
Mechanisms For p38 MAP Kinase DependentT Gene Induction$389,581
R01 · FY2003 · HL
Mechanisms for Stat 3-Mediated Gamma-Globin Gene Silenc*$278,705
R01 · FY2003 · HL
Mechanisms For p38 MAP Kinase DependentT Gene Induction$18,312
R01 · FY2003 · HL
Mechanisms for Stat 3-Mediated Gamma-Globin Gene Silenc*$9,240
R01 · FY2003 · HL
Mechanisms For p38 MAP Kinase DependentT Gene Induction$305,555
R01 · FY2002 · HL
Mechanisms For p38 MAP Kinase DependentT Gene Induction$27,845
R01 · FY2002 · HL
Mechanisms For p38 MAP Kinase DependentT Gene Induction$3,713
R01 · FY2002 · HL
NOVEL MECHANISM FOR GLOBIN GENE SILENCING DURING ALTERNATE LINEAGE COMMITMENT$0
P60 · FY2002 · HL
NOVEL MECHANISM FOR GLOBIN GENE SILENCING DURING ALTERNATE LINEAGE COMMITMENT$0
P60 · FY2002 · HL
Mechanisms For p38 MAP Kinase Dependent Gene Induction$326,157
R01 · FY2001 · HL
NOVEL MECHANISM FOR GLOBIN GENE SILENCING DURING ALTERNATE LINEAGE COMMITMENT$0
P60 · FY2001 · HL
MECHANISMS INVOLVED IN THE INDUCTION OF FETAL HEMOGLOBIN$133,650
K14 · FY2000 · HL
NOVEL MECHANISM FOR GLOBIN GENE SILENCING DURING ALTERNATE LINEAGE COMMITMENT$94,037
P60 · FY2000 · HL